PDCD1 and colorectal carcinoma: Future directions of investigation may seek to explore the utility of a comprehensive assessment that takes into account features of the TME and other immune parameters to produce a composite score predictive of benefit to PD-1/PD-L1 blockade; one such tool, the Immunoscore, has already been demonstrated as a strong prognostic indicator in CRC with potential to guide immunotherapy strategies [66].